[go: up one dir, main page]

WO2011058449A3 - Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use - Google Patents

Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use Download PDF

Info

Publication number
WO2011058449A3
WO2011058449A3 PCT/IB2010/003220 IB2010003220W WO2011058449A3 WO 2011058449 A3 WO2011058449 A3 WO 2011058449A3 IB 2010003220 W IB2010003220 W IB 2010003220W WO 2011058449 A3 WO2011058449 A3 WO 2011058449A3
Authority
WO
WIPO (PCT)
Prior art keywords
bdnf
brain
neurotrophic factor
derived neurotrophic
ophthalmic preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/003220
Other languages
French (fr)
Other versions
WO2011058449A2 (en
Inventor
Luciano Domenici
Luca Giovannini
Marco Sanso'
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HMFRA HUNGARY LLC
Original Assignee
HMFRA HUNGARY LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42211955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011058449(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL10809037T priority Critical patent/PL2501362T3/en
Priority to BR112012011542A priority patent/BR112012011542A2/en
Priority to CN2010800516551A priority patent/CN102639111A/en
Priority to DK10809037.4T priority patent/DK2501362T3/en
Priority to CA2781008A priority patent/CA2781008C/en
Priority to RU2012120096/15A priority patent/RU2564920C2/en
Priority to RS20140644A priority patent/RS53687B1/en
Priority to KR1020127012512A priority patent/KR101831793B1/en
Application filed by HMFRA HUNGARY LLC filed Critical HMFRA HUNGARY LLC
Priority to MX2012005624A priority patent/MX341502B/en
Priority to HRP20141129AT priority patent/HRP20141129T1/en
Priority to SI201030793T priority patent/SI2501362T1/en
Priority to EP10809037.4A priority patent/EP2501362B1/en
Priority to US13/509,824 priority patent/US9387164B2/en
Priority to JP2012538434A priority patent/JP2013510844A/en
Priority to ES10809037.4T priority patent/ES2524976T3/en
Publication of WO2011058449A2 publication Critical patent/WO2011058449A2/en
Publication of WO2011058449A3 publication Critical patent/WO2011058449A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to ophthalmic preparations in the form of eyedrops based on BDNF (Brain-Derived Neurotrophic Factor). Said preparations can be administered topically to the intact eye surface, and are useful in the prevention and treatment of neurodegenerative disorders of the retina, optic nerve, lateral geniculate body and visual cortex, in order to prevent reduction of visual capacity and restore the normal visual function.
PCT/IB2010/003220 2009-11-16 2010-11-12 Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use Ceased WO2011058449A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
ES10809037.4T ES2524976T3 (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on BDNF (Brain Derived Neurotrophic Factor) and its uses
BR112012011542A BR112012011542A2 (en) 2009-11-16 2010-11-12 bdnf-based ophthalmic preparations (brain-derived neurotrophic factor) and their use
CN2010800516551A CN102639111A (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on BDNF (brain-derived neurotrophic factor) and uses thereof
DK10809037.4T DK2501362T3 (en) 2009-11-16 2010-11-12 Ophthalmic compositions are based on BDNF (Brain-Derived Neurotrophic Factor), and use thereof
CA2781008A CA2781008C (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use
RU2012120096/15A RU2564920C2 (en) 2009-11-16 2010-11-12 Bdnf-based (brain-derived neurotrophic factor) ophthalmic preparations and using them
RS20140644A RS53687B1 (en) 2009-11-16 2010-11-12 BDNF-based ophthalmic preparations ("BRAIN-DERIVED NEUROTROPHIC FACTOR") AND THEIR USE
KR1020127012512A KR101831793B1 (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on BDNF (brain-derived neurotrophic factor) and their use
MX2012005624A MX341502B (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use.
PL10809037T PL2501362T3 (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use
EP10809037.4A EP2501362B1 (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use
SI201030793T SI2501362T1 (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use
HRP20141129AT HRP20141129T1 (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use
US13/509,824 US9387164B2 (en) 2009-11-16 2010-11-12 Methods of treating chronic simple glaucoma with ophthalmic preparations based on BDNF (brain-derived neurotrophic factor)
JP2012538434A JP2013510844A (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on BDNF (brain-derived neurotrophic factor) and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2009A002012 2009-11-16
ITMI2009A002012A IT1396607B1 (en) 2009-11-16 2009-11-16 OPHTHALMIC PREPARATIONS BASED ON BDNF (BRAIN-DERIVED NEUROTROPHIC FACTOR) AND THEIR USE.

Publications (2)

Publication Number Publication Date
WO2011058449A2 WO2011058449A2 (en) 2011-05-19
WO2011058449A3 true WO2011058449A3 (en) 2011-12-01

Family

ID=42211955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/003220 Ceased WO2011058449A2 (en) 2009-11-16 2010-11-12 Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use

Country Status (20)

Country Link
US (1) US9387164B2 (en)
EP (1) EP2501362B1 (en)
JP (2) JP2013510844A (en)
KR (1) KR101831793B1 (en)
CN (2) CN105769750A (en)
BR (1) BR112012011542A2 (en)
CA (1) CA2781008C (en)
CL (1) CL2012001267A1 (en)
CY (1) CY1115853T1 (en)
DK (1) DK2501362T3 (en)
ES (1) ES2524976T3 (en)
HR (1) HRP20141129T1 (en)
IT (1) IT1396607B1 (en)
MX (1) MX341502B (en)
PL (1) PL2501362T3 (en)
PT (1) PT2501362E (en)
RS (1) RS53687B1 (en)
RU (1) RU2564920C2 (en)
SI (1) SI2501362T1 (en)
WO (1) WO2011058449A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913468YA (en) * 2015-07-13 2020-03-30 Tohoku Techno Arch Co Ltd Composition for optic nerve protection
ITUA20162343A1 (en) * 2016-04-06 2017-10-06 Luciano Domenici INTRANASAL FORMULATIONS OF BDNF FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
CN111317814B (en) * 2020-04-23 2020-12-18 中国中医科学院眼科医院 Borneol and neurotrophic factor combined composition and application
EP4616865A1 (en) * 2024-03-13 2025-09-17 Dompe' Farmaceutici SpA Bdnf for the treatment of rhodopsin-mediated retinitis pigmentosa

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0958831A1 (en) * 1996-09-13 1999-11-24 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
JP2003048851A (en) * 2001-08-03 2003-02-21 Nidek Co Ltd Medicine for treating visual cell disorder or disease
WO2009044423A1 (en) * 2007-10-02 2009-04-09 Rmfa Trading S.A. Ophthalmic compositions based on tamarind seed polysaccharide and hyaluronic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283911B1 (en) * 1996-02-05 1998-05-07 Farmigea Spa VISCOSIZED OPHTHALMIC SOLUTIONS WITH TAMARIND GUM POLYSACCHARIDES
JPH10212241A (en) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Formulation containing BDNF stably
IT1305294B1 (en) 1999-01-29 2001-05-04 Alessandro Lambiase USE OF THE NERVE GROWTH FACTOR IN THE THERAPY OF PATHOLOGIES DEPENDING ON INTRAOCULAR TISSUES.
WO2006046584A1 (en) 2004-10-26 2006-05-04 Santen Pharmaceutical Co., Ltd. Remedy for visual cell injuries
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
WO2007101204A1 (en) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0958831A1 (en) * 1996-09-13 1999-11-24 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
JP2003048851A (en) * 2001-08-03 2003-02-21 Nidek Co Ltd Medicine for treating visual cell disorder or disease
WO2009044423A1 (en) * 2007-10-02 2009-04-09 Rmfa Trading S.A. Ophthalmic compositions based on tamarind seed polysaccharide and hyaluronic acid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200344, Derwent World Patents Index; AN 2003-461699, XP002586588 *
GHELARDI EMILIA ET AL: "A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis.", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY SEP 2004 LNKD- PUBMED:15328102, vol. 48, no. 9, September 2004 (2004-09-01), pages 3396 - 3401, XP002586589, ISSN: 0066-4804 *
ROLANDO MAURIZIO ET AL: "Establishing the tolerability and performance of tamarind seed polysaccharide (TSP) in treating dry eye syndrome: results of a clinical study", BMC OPHTHALMOLOGY, BIOMED CENTRAL, LONDON, GB LNKD- DOI:10.1186/1471-2415-7-5, vol. 7, no. 1, 29 March 2007 (2007-03-29), pages 5, XP021023229, ISSN: 1471-2415 *

Also Published As

Publication number Publication date
CA2781008C (en) 2018-02-06
PT2501362E (en) 2014-12-04
DK2501362T3 (en) 2014-11-17
CA2781008A1 (en) 2011-05-19
CN102639111A (en) 2012-08-15
US9387164B2 (en) 2016-07-12
EP2501362A2 (en) 2012-09-26
CN105769750A (en) 2016-07-20
KR101831793B1 (en) 2018-02-23
US20120258916A1 (en) 2012-10-11
SI2501362T1 (en) 2014-12-31
ITMI20092012A1 (en) 2011-05-17
MX2012005624A (en) 2012-09-28
WO2011058449A2 (en) 2011-05-19
RU2564920C2 (en) 2015-10-10
ES2524976T3 (en) 2014-12-16
PL2501362T3 (en) 2015-02-27
HRP20141129T1 (en) 2015-01-02
KR20120101390A (en) 2012-09-13
CY1115853T1 (en) 2017-01-25
EP2501362B1 (en) 2014-10-08
JP2016026229A (en) 2016-02-12
RU2012120096A (en) 2013-11-20
RS53687B1 (en) 2015-04-30
JP2013510844A (en) 2013-03-28
MX341502B (en) 2016-08-22
CL2012001267A1 (en) 2012-12-07
IT1396607B1 (en) 2012-12-14
BR112012011542A2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
Jin et al. Curcumin can improve Parkinson's disease via activating BDNF/PI3k/Akt signaling pathways
Giaschi et al. The effect of occlusion therapy on motion perception deficits in amblyopia
WO2010075319A3 (en) Method and apparatus for limiting growth of eye length
MX2011013060A (en) Ophthalmic formulations, methods of manufacture, and methods of using same.
WO2012158910A3 (en) Compositions and methods for treating retinal diseases
WO2009105690A3 (en) Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
WO2008029276A8 (en) Compositions and methods for the treatment of ophthalmic disease
WO2011151685A8 (en) N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
MX2009012645A (en) Formulations and methods for treating dry eye.
WO2012061045A3 (en) Methods and compositions for preserving retinal ganglion cells
WO2011058449A3 (en) Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use
EP4279063A3 (en) Ophthalmic pharmaceutical composition, preparation method therefor and application thereof
WO2013189606A3 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
WO2011076368A3 (en) Topical ophthalmic peptide formulation
WO2011045383A3 (en) 2, 6 -diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
CN105477202A (en) Healthcare beautifying eye mask
WO2012136369A8 (en) Ophthalmic preparations based on pacap (pituitary adenylate cyclase activating polypeptide) which restore the normal visual function in early glaucoma
WO2012088044A3 (en) Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity
Aghazadeh Amiri et al. A Comparative Survey of OCT Findings in Fovea of Unilateral Persistent Anisometropic Amblyopic and Normal Fellow Eyes
WO2012105854A3 (en) Compositions for administration to the eye
CN101066280A (en) Eye drop of deep sea water
Sommer Cytokines and pain
WO2008133198A1 (en) Neurite formation promoter
Shawky et al. Duane retraction syndrome, Egyptian study

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080051655.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10809037

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2781008

Country of ref document: CA

Ref document number: 20127012512

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012001267

Country of ref document: CL

Ref document number: 2012538434

Country of ref document: JP

Ref document number: 2012120096

Country of ref document: RU

Ref document number: 1161/KOLNP/2012

Country of ref document: IN

Ref document number: MX/A/2012/005624

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010809037

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13509824

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012011542

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2014/0644

Country of ref document: RS

ENP Entry into the national phase

Ref document number: 112012011542

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120515